(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 26 July 2001 (26.07.2001)

(10) International Publication Number WO 01/53457 A3

(51) International Patent Classification7: 14/00, A61K 39/00, 43/00

(74) Agents: ANTLER, Adriane, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036

(US).

- (21) International Application Number: PCT/US01/01665
- (22) International Filing Date: 18 January 2001 (18.01.2001)
- (25) Filing Language:

English

C07K 5/00.

(26) Publication Language:

English

(30) Priority Data: 09/489,219

21 January 2000 (21.01.2000) US

- (71) Applicant: UNIVERSITY OF CONNECTICUT HEALTH CENTER [US/US]; 263 Farmington Avenue, Farmington, CT 06030 (US).
- (72) Inventor: SRIVASTAVA, Pramod, K.; 70 Pheasant Run, Avon, CT 06001 (US).

(81) Designated States (national): AU, CA, JP.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

with international search report

(88) Date of publication of the international search report: 18 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: VACCINES AGAINST NEURODEGENERATIVE DISORDERS

(57) Abstract: The present invention relates to pharmaceutical compositions comprising antigenic molecules for use as vaccines for the treatment and prevention of neurodegenerative disorders and diseases, such as Alzheimer's Disease. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for treating and protecting against such neurodegenerative disorders and disease.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/01665

A. CLASSIFICATION OF SUBJECT MATTER					
` '	C07K 5/00, 14/00; A61K 59/00, 45/00				
	550/500, 550; 424/1.11, 184.1 International Patent Classification (IPC) or to bo	th national classification and IPC			
	DS SEARCHED				
	cumentation searched (classification system follow	ed by classification symbols)			
	30/300, 350; 424/1.11, 184.1	,,			
0.5 0	20, 200, 320, 427, 1.11, 1.07.1				
Documentati searched Searched sea	on searched other than minimum documentation trich	to the extent that such documents are i	ncluded in the fields		
Electronic da Medline, V	ata base consulted during the international search ((name of data base and, where practicabl	e, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.		
x	Cederbaum, J.M. A Phase I Study of	Recombinant Human Ciliary	1-3, 5, 16, 26,		
	Neurotrophic Factor (rHCNTF) in Pati	28,			
Y		ogy. 1995. Vol. 18. No. 6.			
	pages 515-532, especially abstract.		1-33		
Y	Sanan. D.A. Apolipoprotein E Associa of Alzheimer's Disease to Form Novel	· · · · · · · · · · · · · · · · · · ·	1-33		
1	August 1994 Vol. 94. pages 860-869	€			
Y	LaDu M.J. Purification of Apolipop Specific Binding to Beta Amyloid. J. Vol. 270. No. 16. pages 9039-42		1-33		
			<u>.</u>		
X Further documents are listed in the continuation of Box C. See patent family annex.					
Special categories of cited documents: "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand					
	ment defining the general state of the art which is not considered of particular relevance	the principle or theory underlying the			
"E" earlier document published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step					
	ment which may throw doubts on priority claim(s) or which is to establish the publication date of another citation or other	when the document is taken alone			
	al reason (as specified)	"Y" document of particular relevance; the considered to involve an inventive step			
	Considered to involve an inventive step when the document is combined O" document referring to an oral disclosure, use, exhibition or other with one or more other such documents, such combination being obvious to a person skilled in the art				
	P" document published prior to the international filing date but later "&" document member of the same patent family than the priority date claimed				
Date of the actual completion of the international search Date of mailing of the international search report					
19 JUNE 2	19 JUNE 2001 27 JUL 2001				
	uiling address of the ISA/US or of Patents and Trademarks	Authorized officer, SHARON L. TURNER			
wasningion,	(70e) eos eoso	Tolorbana Nia (708) MOR COS	4		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/01665

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	McGeer. P.L. Apolipoprotein E4(ApoE4) but not ApoE3 or ApoE2 potentiates Beta-amyloid protein activation of complement in vitro. Brain Research. 1997. Vol. 749. pages 135-138.	1-33
X Y	AL-SABBAGH. A.M. Decreased CNS Inflammation and Absence of Clinical Exacerbation of Disease After Six Months Oral Administration of Bovine Myelin in Diseased SJL/J Mice with Chronic Relapsing Experimental Autoimmune Encephalomyelitis. J. of Neuroscience Research. 1996. Vol. 45. pages 424-429	1-3, 5, 16, 26, 28 1-33
X - Y	US 5,739,109 A (GALPIN ET AL) 14 April 1998 (14-04-95), see entire document, especially claims.	1-3, 5, 16, 26, 28 1-33
X Y	US 5,811,243 (STRITTMATTER ET AL) 22 September 1998 (22-09-98) columns 2-3.	1-6, 16-20, 26, 28 1-33
Y	US 5,780,587 A (POTTER) 14 July 1998 (14-07-98), columns 2-3.	1-33
	·	